Initial treatment for management of mild to moderate Crohn’s disease is:
**Core Concept**
The initial treatment for managing mild to moderate Crohn's disease involves the use of aminosalicylates or immunomodulators to reduce inflammation and induce remission. This approach aims to minimize the use of corticosteroids and their associated side effects.
**Why the Correct Answer is Right**
The correct answer is **C. Azathioprine**. Azathioprine is an immunomodulator that works by inhibiting purine synthesis, thereby reducing the proliferation of T and B lymphocytes. This leads to a decrease in the production of inflammatory cytokines, such as TNF-alpha and IL-1 beta, which contribute to the pathogenesis of Crohn's disease. Azathioprine is often used in combination with aminosalicylates, like sulfasalazine, to achieve better results.
**Why Each Wrong Option is Incorrect**
**Option A:** Aminosalicylates, such as sulfasalazine, are effective in treating mild to moderate ulcerative colitis but are less effective in Crohn's disease, particularly in patients with extensive small bowel involvement.
**Option B:** Corticosteroids, like prednisone, are effective in inducing remission in Crohn's disease but are associated with significant side effects, including osteoporosis, diabetes, and cardiovascular disease. They are typically reserved for moderate to severe disease or as a bridge to other therapies.
**Option D:** JAK inhibitors, such as tofacitinib, are a relatively new class of medications that target the JAK-STAT pathway. While they have shown promise in treating moderate to severe Crohn's disease, they are not typically used as initial therapy due to concerns about safety and efficacy.
**Clinical Pearl / High-Yield Fact**
When initiating treatment for Crohn's disease, it's essential to consider the patient's disease location, behavior, and extent, as well as their medical and surgical history. Aminosalicylates or immunomodulators should be used as the first-line therapy, while corticosteroids and biologics are reserved for more severe disease or as add-on therapy.
**Correct Answer: C. Azathioprine**